BioXcel Submits sNDA for IGALMI® in At-Home Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BTAI?
Source: Newsfilter
- At-Home Treatment Application: BioXcel submitted a supplemental New Drug Application (sNDA) to the FDA in January 2026 for IGALMI® to expand its indication for treating acute agitation associated with bipolar disorders and schizophrenia in the at-home setting, with potential approval as early as year-end 2026, thereby addressing a significant market gap and enhancing the company's competitive position in mental health.
- Market Opportunity Assessment: The company confirmed the substantial market potential for IGALMI in the at-home treatment space through a third-party market assessment, revealing up to 86 million annual episodes of acute agitation that may require treatment, which strongly supports BioXcel's commercial strategy and is expected to drive future revenue growth.
- Commercial Preparation Progress: BioXcel appointed Mark Pavao as Interim Chief Commercial Officer to lead the launch plans for IGALMI in the at-home setting, indicating the company's commitment to capitalizing on market opportunities and enhancing brand awareness and market penetration through effective commercial strategies.
- Financial Performance Review: In Q4 2025, IGALMI generated net revenue of $256,000, down from $366,000 in Q4 2024; nevertheless, the company is actively advancing IGALMI's market promotion and brand maintenance to tackle future market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTAI
Wall Street analysts forecast BTAI stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 1.260
Low
1.00
Averages
5.50
High
10.00
Current: 1.260
Low
1.00
Averages
5.50
High
10.00
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioXcel Submits sNDA for IGALMI® in At-Home Treatment
- At-Home Treatment Application: BioXcel submitted a supplemental New Drug Application (sNDA) to the FDA in January 2026 for IGALMI® to expand its indication for treating acute agitation associated with bipolar disorders and schizophrenia in the at-home setting, with potential approval as early as year-end 2026, thereby addressing a significant market gap and enhancing the company's competitive position in mental health.
- Market Opportunity Assessment: The company confirmed the substantial market potential for IGALMI in the at-home treatment space through a third-party market assessment, revealing up to 86 million annual episodes of acute agitation that may require treatment, which strongly supports BioXcel's commercial strategy and is expected to drive future revenue growth.
- Commercial Preparation Progress: BioXcel appointed Mark Pavao as Interim Chief Commercial Officer to lead the launch plans for IGALMI in the at-home setting, indicating the company's commitment to capitalizing on market opportunities and enhancing brand awareness and market penetration through effective commercial strategies.
- Financial Performance Review: In Q4 2025, IGALMI generated net revenue of $256,000, down from $366,000 in Q4 2024; nevertheless, the company is actively advancing IGALMI's market promotion and brand maintenance to tackle future market challenges.
See More
BioXcel Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: BioXcel Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.06, indicating a degree of financial resilience despite challenges.
- Revenue Trends: The company generated $260,000 in revenue, a 29.7% year-over-year decline, yet it surpassed market expectations by $110,000, suggesting some level of market demand amid adversity.
- Cash Position: As of December 31, 2025, BioXcel's cash and cash equivalents, along with restricted cash, totaled $28.8 million, ensuring liquidity for future operations.
- R&D Progress: BioXcel Therapeutics has made advancements in Phase III results for treating acute agitation in Alzheimer's dementia, potentially laying the groundwork for future product line expansion.
See More
BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering
- Funding Size: BioXcel Therapeutics has entered into a securities purchase agreement with an institutional investor to issue 4,500,785 shares at $1.739 per share, resulting in approximately $8 million in gross proceeds, which will enhance the company's liquidity for R&D support.
- Warrant Terms: The accompanying warrants allow for exercise at $1.614 per share over five years, which is expected to attract more investor participation, thereby boosting market confidence and shareholder value.
- Existing Warrant Adjustment: BioXcel will also reduce the exercise price of previously issued warrants for 1,385,083 shares to $1.614 and extend their expiration, aiming to enhance the attractiveness of existing investors' holdings and promote long-term investment.
- Transaction Timeline: The offering is expected to close on March 11, 2026, subject to customary closing conditions, and if successful, will provide funding support for the company's future strategic development.
See More
BioXcel Therapeutics Shares Decline Despite Positive Drug Development News
- Drug Development Progress: BioXcel Therapeutics' BXCL501 demonstrated efficacy in a Phase 2 study led by Columbia University for treating opioid withdrawal symptoms, with over a 30% reduction in symptoms observed in patients, indicating the drug's potential across multiple indications.
- Stock Price Analysis: Despite the positive results from BXCL501, BioXcel's shares are currently priced at $1.52, trading 3.9% below the 20-day simple moving average and 17.9% below the 100-day SMA, indicating a lack of upward momentum in the short term.
- Long-term Performance Weakness: The stock has decreased approximately 41.24% over the past 12 months and is closer to its 52-week lows, reflecting market concerns about its future performance, although the relative strength index (RSI) at 46.86 suggests a neutral state.
- Market Sentiment Analysis: While the overall trend is bearish, the MACD at -0.0166 is above its signal line, indicating some bullish momentum that may present short-term trading opportunities for investors.
See More
BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT
Stock Performance: BioXcel Therapeutics shares have increased by 2.7%.
Clinical Trial Results: An experimental opioid withdrawal drug shows benefits in mid-stage trials.
See More
BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics' Phase 2 study indicates that BXCL501 is as effective as or superior to BioCorRx's lofexidine in reducing opioid withdrawal symptoms, with a more convenient dosing regimen potentially offering better treatment options for patients.
- Significant Symptom Improvement: Patients receiving BXCL501 240 µg experienced over a 30% reduction in Short Opiate Withdrawal Scale (SOWS-Gossop) scores, with peak symptom improvement observed on days 3 and 4, demonstrating BXCL501's efficacy.
- Good Tolerability Profile: BXCL501 showed a favorable tolerability profile compared to lofexidine, with similar or lower rates of cardiovascular side effects, indicating higher safety in clinical applications.
- Huge Market Potential: BXCL501 is viewed as a “pipeline within a product,” with applicability potentially extending to acute agitation associated with bipolar disorder and schizophrenia, signaling future market opportunities.
See More
BioXcel Submits sNDA for IGALMI® in At-Home Treatment
- At-Home Treatment Application: BioXcel submitted a supplemental New Drug Application (sNDA) to the FDA in January 2026 for IGALMI® to expand its indication for treating acute agitation associated with bipolar disorders and schizophrenia in the at-home setting, with potential approval as early as year-end 2026, thereby addressing a significant market gap and enhancing the company's competitive position in mental health.
- Market Opportunity Assessment: The company confirmed the substantial market potential for IGALMI in the at-home treatment space through a third-party market assessment, revealing up to 86 million annual episodes of acute agitation that may require treatment, which strongly supports BioXcel's commercial strategy and is expected to drive future revenue growth.
- Commercial Preparation Progress: BioXcel appointed Mark Pavao as Interim Chief Commercial Officer to lead the launch plans for IGALMI in the at-home setting, indicating the company's commitment to capitalizing on market opportunities and enhancing brand awareness and market penetration through effective commercial strategies.
- Financial Performance Review: In Q4 2025, IGALMI generated net revenue of $256,000, down from $366,000 in Q4 2024; nevertheless, the company is actively advancing IGALMI's market promotion and brand maintenance to tackle future market challenges.
See More
BioXcel Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: BioXcel Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.06, indicating a degree of financial resilience despite challenges.
- Revenue Trends: The company generated $260,000 in revenue, a 29.7% year-over-year decline, yet it surpassed market expectations by $110,000, suggesting some level of market demand amid adversity.
- Cash Position: As of December 31, 2025, BioXcel's cash and cash equivalents, along with restricted cash, totaled $28.8 million, ensuring liquidity for future operations.
- R&D Progress: BioXcel Therapeutics has made advancements in Phase III results for treating acute agitation in Alzheimer's dementia, potentially laying the groundwork for future product line expansion.
See More
BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering
- Funding Size: BioXcel Therapeutics has entered into a securities purchase agreement with an institutional investor to issue 4,500,785 shares at $1.739 per share, resulting in approximately $8 million in gross proceeds, which will enhance the company's liquidity for R&D support.
- Warrant Terms: The accompanying warrants allow for exercise at $1.614 per share over five years, which is expected to attract more investor participation, thereby boosting market confidence and shareholder value.
- Existing Warrant Adjustment: BioXcel will also reduce the exercise price of previously issued warrants for 1,385,083 shares to $1.614 and extend their expiration, aiming to enhance the attractiveness of existing investors' holdings and promote long-term investment.
- Transaction Timeline: The offering is expected to close on March 11, 2026, subject to customary closing conditions, and if successful, will provide funding support for the company's future strategic development.
See More
BioXcel Therapeutics Shares Decline Despite Positive Drug Development News
- Drug Development Progress: BioXcel Therapeutics' BXCL501 demonstrated efficacy in a Phase 2 study led by Columbia University for treating opioid withdrawal symptoms, with over a 30% reduction in symptoms observed in patients, indicating the drug's potential across multiple indications.
- Stock Price Analysis: Despite the positive results from BXCL501, BioXcel's shares are currently priced at $1.52, trading 3.9% below the 20-day simple moving average and 17.9% below the 100-day SMA, indicating a lack of upward momentum in the short term.
- Long-term Performance Weakness: The stock has decreased approximately 41.24% over the past 12 months and is closer to its 52-week lows, reflecting market concerns about its future performance, although the relative strength index (RSI) at 46.86 suggests a neutral state.
- Market Sentiment Analysis: While the overall trend is bearish, the MACD at -0.0166 is above its signal line, indicating some bullish momentum that may present short-term trading opportunities for investors.
See More
BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT
Stock Performance: BioXcel Therapeutics shares have increased by 2.7%.
Clinical Trial Results: An experimental opioid withdrawal drug shows benefits in mid-stage trials.
See More
BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics' Phase 2 study indicates that BXCL501 is as effective as or superior to BioCorRx's lofexidine in reducing opioid withdrawal symptoms, with a more convenient dosing regimen potentially offering better treatment options for patients.
- Significant Symptom Improvement: Patients receiving BXCL501 240 µg experienced over a 30% reduction in Short Opiate Withdrawal Scale (SOWS-Gossop) scores, with peak symptom improvement observed on days 3 and 4, demonstrating BXCL501's efficacy.
- Good Tolerability Profile: BXCL501 showed a favorable tolerability profile compared to lofexidine, with similar or lower rates of cardiovascular side effects, indicating higher safety in clinical applications.
- Huge Market Potential: BXCL501 is viewed as a “pipeline within a product,” with applicability potentially extending to acute agitation associated with bipolar disorder and schizophrenia, signaling future market opportunities.
See More
